Biogen Q3 results better than expected, updrades guidance

The US-based biotech company Biogen has released its Q3 report for 2021, stating that sales and revenue decrease was smaller than expected – subsequently, financial guidance is upgraded.
Photo: Brian Snyder/Reuters/Ritzau Scanpix
Photo: Brian Snyder/Reuters/Ritzau Scanpix
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

The US premarket indicator for Biogen stock is up 1.8 percent at USD 273.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading